CARM1 promotes gastric cancer progression by regulating TFE3 mediated autophagy enhancement through the cytoplasmic AMPK-mTOR and nuclear AMPK-CARM1-TFE3 signaling pathways

Table 1 Prognostic factors in gastric cancer patients by univariate analysis

Parameter	n	Cumulative survival rates (%)		Mean survival time (month)	Hazard ratio	95% Confidence interval	P- value
Parameter	n	3-year	5-year	Mean survival time (month)	Hazard ratio	95% Confidence interval	P- value
Gender
Male	30	82.3	76.5	66.128	2.642	0.883–7.905	0.082
Female	18	57.2	57.2	47.510	2.642	0.883–7.905	0.082
Age
< 60	26	70.5	70.5	58.749	0.911	0.306–2.716	0.867
≥ 60	22	76.5	69.5	61.513	0.911	0.306–2.716	0.867
Location
Antrum	16	81.3	81.3	64.961
Cardia fundus	22	70.3	70.3	58.975	1.768	0.44–7.096	0.422
gastric body	7	85.7	85.7	64.611	0.948	0.098–9.122	0.963
Full stomach	3	33.3	0	34.897	6.093	1.216–30.532	0.028
Tumor size
< 5 cm	29	82.6	82.6	64.143	2.649	0.864–8.124	0.088
≥ 5 cm	19	57.6	48.0	52.100	2.649	0.864–8.124	0.088
Lymph node metastasis
Negative	20	85.0	85.0	67.608	3.049	0.835–11.132	0.091
Positive	28	63.5	55.6	53.380	3.049	0.835–11.132	0.091
Metastasis
Negative	44	78.2	73.9	62.904	3.907	1.072–14.234	0.039
Positive	4	25.0	25.0	31.048	3.907	1.072–14.234	0.039
Vessel carcinoma embolus
Negative	44	73.1	68.8	59.570	0.852	0.111–6.555	0.878
Positive	3	75.0	75.0	61.630	0.852	0.111–6.555	0.878
CARM1 level
Low	18	93.3	93.3	74.023	8.489	1.103–65.343	0.04
High	30	61.8	56.2	51.956	8.489	1.103–65.343	0.04

ISSN: 1475-2867